Last updated on January 2020

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia.


Brief description of study

The purpose of this study is to gather and evaluate additional safety and efficacy data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidation

Clinical Study Identifier: NCT03379727

Find a site near you

Start Over

Novartis Investigative Site

Saint Priest en Jarez, France
  Connect »

Novartis Investigative Site

Pierre Benite Cedex, France
  Connect »

Novartis Investigative Site

San Giovanni Rotondo, Italy
  Connect »

Novartis Investigative Site

Banska Bystrica, Slovakia
  Connect »

Novartis Investigative Site

Pozuelo de Alarcon, Spain
  Connect »

Novartis Investigative Site

Las Palmas de Gran Canaria, Spain
  Connect »